The GSK share price has hit a 5-year low! Here’s why I’d buy today

The GSK share price has slumped over 30% in little more than a year. This Fool reckons the stock offers him long-term value.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has been out of favour with the market for some time. Its recent results did nothing to improve sentiment. Indeed, the GSK share price slumped to a five-year low last week.

The stock looks very buyable to me right now. Here, I’ll discuss why I think it’s attractive, as well as the potential risks.

Decline of the GSK share price

Little more than a year ago, GSK’s shares hit a peak of 1,846p. From there to last week’s five-year low of 1,255p is a decline of 32%. That’s some swing in market sentiment!

Results on 3 February produced the final push into multi-year-low territory. The GSK share price suffered a one-day fall of over 6%.

Performance and outlook

GSK’s headline numbers didn’t appear to me to merit such a drop in the share price. The company reported a 3% rise in sales and a 4% fall in adjusted earnings per share (EPS) at constant exchange rates (CER), “in line with guidance.”

I think the market was disappointed by the company’s outlook for 2021. Management said it expects modest sales growth and “a decline of mid to high-single digit percent adjusted EPS at CER.” The 2022 outlook though, remained unchanged. The company continues to expect a “meaningful improvement in revenues and margins.”

GSK’s dividend news may also have negatively affected the share price. The board maintained the 2020 payout and expects to maintain it in 2021. However, to support growth and investment, the company said it will be implementing a new dividend policy in 2022 under which “we expect that aggregate distributions for GSK will be lower than at present.”

Looking longer term

I think the market is perhaps being short-sighted. Near-term sales are expected to be anaemic and earnings subdued due to investment in R&D and the promotion of new product launches. The business hasn’t been entirely immune to the impact of the Covid-19 pandemic either. Finally, the preparations for demerging the consumer healthcare business in 2022 are also weighing on near-term performance.

However, in the longer term, I see plenty to encourage me that GSK offers significant value at the current share price. The company reported “strong growth of new and specialty products” in 2020. Its biopharma pipeline has “over 20 assets now in late-stage clinical trials.” These include “10+ with potential peak annual revenues in excess of $1bn.”

Meanwhile, the demerger of the consumer healthcare business, with its £10bn annual sales, will create a standalone global leader in the sector.

Why I like the GSK share price

GSK’s shares are off last week’s low, being priced at 1,278p, as I’m writing. This is 11 times the group’s 2020 EPS.

The consumer healthcare business contributed 25% to operating profit. I see no reason why this business shouldn’t command an earnings rating similar to consumer health and hygiene company Reckitt Benckiser.

I can understand the market being hesitant to rate the pharma side of the business highly at the moment. After all, there’s a risk its pipeline may not be as productive or lucrative as management currently anticipates.

However, if I rate the consumer business at a Reckitt Benckiser-style 20 times earnings, and the pharma business at the modest 11 times earnings, I arrive at an aggregate 13.25 times earnings, and fair value for the GSK share price of 1,536p.

Despite the aforementioned pipeline risk, I see potential upside for GSK of over 20% excluding dividends.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much would I need to invest in income shares to earn £300 a month?

What kind of lump sum would be required to earn £300 a month by taking advantage of some of the…

Read more »

Investing For Beginners

Up 31% in a month, could this FTSE 250 stock be getting bought out?

Jon Smith takes a look at speculation that's pushing the share price of a FTSE 250 share higher and considers…

Read more »

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »